The role for saxagliptin within the management of type 2 diabetes mellitus: an update from the 2010 European Association for the Study of Diabetes (EASD) 46th annual meeting and the American Diabetes Association (ADA) 70th scientific session
2010

Saxagliptin for Managing Type 2 Diabetes

publication Evidence: moderate

Author Information

Author(s): Pablo J Aschner

Primary Institution: Javeriana University

Hypothesis

Can saxagliptin improve glycemic control in patients with type 2 diabetes without increasing the risk of hypoglycemia?

Conclusion

Saxagliptin is effective in lowering HbA1c levels in type 2 diabetes patients without increasing the risk of hypoglycemia.

Supporting Evidence

  • Saxagliptin combination therapy improves HbA1c levels compared with placebo.
  • Saxagliptin has a low risk of hypoglycemia, making it more acceptable for patients.
  • Saxagliptin is well-tolerated in patients with renal impairment.

Takeaway

Saxagliptin helps people with diabetes lower their blood sugar without making them feel shaky or sick from low blood sugar.

Methodology

The study involved pooled analyses of Phase III trials and comparisons of saxagliptin with placebo and other treatments.

Limitations

The study results are based on abstracts and may not include all adverse events.

Participant Demographics

Patients with type 2 diabetes aged over 18 years with varying baseline characteristics.

Statistical Information

P-Value

p<0.0001

Statistical Significance

p<0.0001

Digital Object Identifier (DOI)

10.1186/1758-5996-2-69

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication